Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study-Reference-Cited by-同舟云学术

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study

Published:2016-12-22 Issue:4 Volume:66 Page:441-449
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Weide Benjamin,Martens Alexander,Wistuba-Hamprecht Kilian,Zelba Henning,Maier Ludwig,Lipp Hans-Peter,Klumpp Bernhard D.,Soffel Daniel,Eigentler Thomas K.,Garbe Claus

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1944-0.pdf

Reference43 articles.

1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–2116

2. Vlasveld LT, Horenblas S, Hekman A, Hilton AM, Dubbelman AC, Melief CJ et al (1994) Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol 5(2):179–181

3. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W et al (2003) Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 21(15):2883–2888